Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Tideglusib Versus Placebo for the Treatment of Children and Adolescents With Congenital Myotonic Dystrophy (REACH CDM)

NCT03692312 is registered in ClinicalTrials.gov with AMO Pharma Limited as lead sponsor.

NCT NCT03692312
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03692312 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Tideglusib Versus Placebo for the Treatment of Children and Adolescents With Congenital Myotonic Dystrophy (REACH CDM)
Lead sponsor
AMO Pharma Limited
Phase
Phase 2/3
Overall status
Completed
Start date
March 3, 2021
Completion date
April 4, 2023
Enrollment
56 (actual)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

congenital myotonic dystrophy